



PRESS RELEASES

[View printer-friendly version](#)

[<< Back](#)

Ironwood Closes \$150 Million Debt Refinancing

- Proceeds will be used to redeem all outstanding Linaclotide PhaRMASM 11% Notes -

- Refinancing reduces cost of capital with interest rate of 8.375% -

- Transaction expected to fund in early January 2017, subject to and concurrent with redemption of existing PhaRMA Notes -

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- [Ironwood Pharmaceuticals, Inc.](#) (NASDAQ:IRWD) today announced the closing of a \$150 million debt refinancing. Ironwood will use the net proceeds from this transaction to redeem the remaining principal balance of its existing Linaclotide PhaRMA 11% Notes due 2024.

The \$150 million in aggregate principal amount of Notes will have a legal maturity of September 15, 2026 and will bear an annual interest rate of 8.375%. Interest on the 8.375% Notes will be paid quarterly beginning June 15, 2017, and principal will be payable quarterly beginning March 15, 2019. Issuance of the 8.375% Notes is subject to full redemption of the existing PhaRMA Notes. The 8.375% Notes and the existing PhaRMA Notes are expected to be issued and redeemed, respectively, in early January 2017 when the prepayment penalty associated with the existing PhaRMA Notes ceases.

Consistent with the PhaRMA Notes payment structure, Ironwood will make quarterly payments on the 8.375% Notes after the interest-only period in an amount equal to the greater of (i) 7.5% of net sales of linaclotide in the United States for the preceding quarter ("the synthetic royalty amount") and (ii) accrued and unpaid interest on the 8.375% Notes ("the required interest amount"). Principal on the 8.375% Notes will be repaid in an amount equal to the synthetic royalty amount minus the required interest amount, when this is a positive number, until the principal has been paid in full. Given that the principal payments on the 8.375% Notes are based on the synthetic royalty amount, which will vary from quarter to quarter, the 8.375% Notes are expected to be fully repaid prior to the final maturity date in 2026.

The 8.375% Notes will be secured by a security interest in a segregated bank account established to receive the required quarterly payments, as well as certain limited accounts receivables, payment intangibles or other rights to payment or proceeds, in each case, up to the synthetic royalty amount or its estimated equivalent, as applicable. The 8.375% Notes are not convertible into Ironwood equity. The 8.375% Notes may be redeemed at any time prior to maturity, in whole or in part, at the option of Ironwood at specified redemption premiums.

Funds affiliated with TSSP, a leading special situations investment platform, will be the purchasers of the 8.375% Notes.

For further details on the terms and conditions of the 8.375% Notes, please refer to the Form 8-K filed today with the Securities and Exchange Commission.

The current principal balance on the existing PhaRMA Notes is approximately \$143 million.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology company focused on creating medicines that make a difference for patients, building value for our fellow shareholders, and empowering our passionate team. We are advancing a pipeline of innovative medicines in areas of significant unmet need, including irritable bowel syndrome with constipation (IBS-C)/chronic idiopathic constipation (CIC), uncontrolled gout, refractory gastroesophageal reflux disease, and vascular and fibrotic diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader in the IBS-C/CIC category, and we are applying our proven R&D and commercial capabilities to advance multiple internally-developed and externally-accessed product opportunities. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. For more information, please visit www.ironwoodpharma.com; information that may be important to investors will be routinely posted in this location.

This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our expectations concerning the completion of the issuance and sale of the 8.375% Notes, the timing of the repayment of the 8.375% Notes and the timing of, and our ability to complete, the redemption of the PhaRMA Notes. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risk that we are unable to successfully complete the issuance and sale of the 8.375% Notes and the redemption of the PhaRMA Notes and the repayment of the 8.375% Notes prior to September 15, 2026; and the risks listed under the heading "Risk Factors" and elsewhere in Ironwood's Quarterly Report on Form 10-Q for the quarter

View source version on [businesswire.com](http://www.businesswire.com/news/home/20160926005507/en/): <http://www.businesswire.com/news/home/20160926005507/en/>

Media Relations:

Trista Morrison, 617-374-5095
Director, Corporate Communications
tmorrison@ironwoodpharma.com
or

Investor Relations:

Meredith Kaya, 617-374-5082
Director, Investor Relations
mkaya@ironwoodpharma.com

Source: Ironwood Pharmaceuticals, Inc.

News Provided by Acquire Media

Ironwood Pharmaceuticals
301 Binney Street
Cambridge, MA 02142
tel 617.621.7722
fax 617.494.0480

Search



ABOUT US

Overview
Core Values
Management Team
Founders
Board of Directors
Pharmaceutical
Advisory Committee
Contact Us
Transparency

OUR MEDICINE

Overview
Discovery of
Linaclotide
Global Strategy

R&D

Overview
sGC Programs
Approach

COLLABORATE

Overview
Accessing Additional
Products
Globalization

INVESTORS

Overview
Business Principles
Events
Corporate Governance
Financial Information
Stock Information
Investor FAQs
Press Releases
Investor Contacts

NEWS

News
Press Releases
Social Media
Multimedia
Resources

JOIN US

Overview
Career Openings
Our Community
Our Expertise